Courtney Finlayson

Courtney Finlayson

Auto-generated profile, based on publicly available information

Courtney Finlayson

Division of Endocrinology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Transgender Health
Verified
Journal Article
Open access
CFCourtney Finlayson
Courtney Finlayson
EJEmilie K. Johnson
Emilie K. Johnson
DCDiane Chen
Diane Chen
EDElizabeth Dabrowski
Elizabeth Dabrowski
YGYasmin Gosiengfiao
Yasmin Gosiengfiao
TWTeresa K. Woodruff
Teresa K. Woodruff
Children and adolescents with gender and sex diversity include (1) gender-nonconforming and transgender individuals for whom gender identity or expression are incongruent with birth-assigned sex (heretofore, transgender) and (2) individuals who have differences in sex development (DSD). Although these are largely disparate groups, there is overlap in the medical expertise necessary to care for individuals with both gender and sex diversity. In addition, both groups face potential infertility or sterility as a result of desired medical and surgical therapies. The Ann & Robert H. Lurie Children's Hospital of Chicago (Lurie Children's) gender and sex development program (GSDP) provides specialized multidisciplinary care for both transgender and DSD patients. In response to patient concerns that recommended medical treatments have the potential to affect fertility, the Lurie Children's GSDP team partnered with experts from the Oncofertility Consortium at Northwestern University to expand fertility preservation options to gender and sex diverse youth. This article summarizes the results of a meeting of experts across this field at the annual Oncofertility Consortium conference with thoughts on next steps toward a unified protocol for this patient group.

1 March 2017 in Journal of Urology
Verified
Journal Article
Closed access
CFCourtney Finlayson
Courtney Finlayson
MFMichael K. Fritsch
Michael K. Fritsch
EJEmilie K. Johnson
Emilie K. Johnson
IRIlina Rosoklija
Ilina Rosoklija
YGYasmin Gosiengfiao
Yasmin Gosiengfiao
ECEarl Cheng
Earl Cheng
We sought to determine the presence of germ cells in the gonads of patients with disorders of sex development to establish whether preservation of germ cells for future fertility potential is possible. We hypothesized that germ cells are present but vary by age and diagnosis. We reviewed histology from patients with disorders of sex development who underwent gonadectomy/biopsy from 2002 to 2014 at a single institution for pathological classification of the gonad, composition of gonadal stroma and germ cell presence. A total of 44 patients were identified and germ cells were present in 68%. The presence and average number of germ cells per mm2 were analyzed by gonad type and diagnosis. By gonad type all ovotestes, most testes, ovaries and dysgenetic testes, and 15% of streak gonads had germ cells present. By diagnosis germ cells were present in all patients with complete androgen insensitivity syndrome, Denys-Drash syndrome, SRY mutation, mixed gonadal dysgenesis, ovotesticular conditions and StAR (steroid acute regulatory protein) deficiency, in some patients with persistent müllerian duct syndrome, XO/XY Turner syndrome and disorders of sex development not otherwise specified, and in none with complete or partial gonadal dysgenesis. Germ cells were present in the gonads of 88% of patients 0 to 3 years old, 50% of those 4 to 11 years old and 43% of those older than 12 years. Germ cells were present in the majority of our cohort and the presence decreased with age. This novel, fertility driven evaluation of germ cell quantity in a variety of disorders of sex development suggests that fertility potential may be greater than previously thought. Further studies must be done to evaluate a larger population and examine germ cell quality to determine the viability of these germ cells.

2 July 2020 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
JLJanet Y Lee
Janet Y Lee
CFCourtney Finlayson
Courtney Finlayson
JOJohanna Olson-Kennedy
Johanna Olson-Kennedy
Robert GarofaloRobert Garofalo
Robert Garofalo
YCYee-Ming Chan
Yee-Ming Chan
SRStephen M Rosenthal
Stephen M Rosenthal
Context: Transgender youth may initiate GnRH agonists (GnRHa) to suppress puberty, a critical period for bone-mass accrual. Low bone mineral density (BMD) has been reported in late-pubertal transgender girls before gender-affirming therapy, but little is known about BMD in early-pubertal transgender youth. Objective: To describe BMD in early-pubertal transgender youth. Design: Cross-sectional analysis of the prospective, observational, longitudinal Trans Youth Care Study cohort. Setting: Four multidisciplinary academic pediatric gender centers in the United States. Participants: Early-pubertal transgender youth initiating GnRHa. Main Outcome Measures: Areal and volumetric BMD Z-scores. Results: Designated males at birth (DMAB) had below-average BMD Z-scores when compared with male reference standards, and designated females at birth (DFAB) had below-average BMD Z-scores when compared with female reference standards except at hip sites. At least 1 BMD Z-score was < -2 in 30% of DMAB and 13% of DFAB. Youth with low BMD scored lower on the Physical Activity Questionnaire for Older Children than youth with normal BMD, 2.32 ± 0.71 vs. 2.76 ± 0.61 (P = 0.01). There were no significant deficiencies in vitamin D, but dietary calcium intake was suboptimal in all youth. Conclusions: In early-pubertal transgender youth, BMD was lower than reference standards for sex designated at birth. This lower BMD may be explained, in part, by suboptimal calcium intake and decreased physical activity–potential targets for intervention. Our results suggest a potential need for assessment of BMD in prepubertal gender-diverse youth and continued monitoring of BMD throughout the pubertal period of gender-affirming therapy.

Verified
Journal Article
Open access
Phyllis W. SpeiserPhyllis W. Speiser
Phyllis W. Speiser
RCReeti Chawla
Reeti Chawla
MCMing Chen
Ming Chen
ADAlicia Diaz-Thomas
Alicia Diaz-Thomas
CFCourtney Finlayson
Courtney Finlayson
EDEmmanuèle Délot
Emmanuèle Délot
Newborn screening for congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency is mandated throughout the US. Filter paper blood specimens are assayed for 17-hydroxyprogesterone (17OHP). Prematurity, low birth weight, or critical illness cause falsely elevated results. The purpose of this report is to highlight differences in protocols among US state laboratories. We circulated a survey to state laboratory directors requesting qualitative and quantitative information about individual screening programs. Qualitative and quantitative information provided by 17 state programs were available for analysis. Disease prevalence ranged from 1:9941 to 1:28,661 live births. Four state laboratories mandated a second screen regardless of the initial screening results; most others did so for infants in intensive care units. All but one program utilized birthweight cut-points, but cutoffs varied widely: 17OHP values of 25 to 75 ng/mL for birthweights >2250–2500 g. The positive predictive values for normal birthweight infants varied from 0.7% to 50%, with the highest predictive values based in two of the states with a mandatory second screen. Data were unavailable for negative predictive values. These data imply differences in sensitivity and specificity in CAH screening in the US. Standardization of newborn screening protocols could improve the positive predictive value.

14 May 2020 in Journal of Adolescent Health
Verified
Journal Article
Closed access
KMKate Millington
Kate Millington
CSCaroline Schulmeister
Caroline Schulmeister
CFCourtney Finlayson
Courtney Finlayson
RGRen Grabert
Ren Grabert
JOJohanna Olson-Kennedy
Johanna Olson-Kennedy
YCYee-Ming Chan
Yee-Ming Chan

18 August 2020 in Journal of Adolescent Health
Verified
Journal Article
Closed access
KQKit M. Quain
Kit M. Quain
MKMoira A. Kyweluk
Moira A. Kyweluk
ASAfiya Sajwani
Afiya Sajwani
SGSiobhan Gruschow
Siobhan Gruschow
CFCourtney Finlayson
Courtney Finlayson
DCDiane Chen
Diane Chen